Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Brexpiprazole in Bipolar I Disorder
2017-002225-38Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Primary safety endpoint. Started Nov 2017; status: completed.
02
Drugs
brexpiprazole
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2017-002225-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002225-38.